Medscape Medical News from the

American Diabetes Association (ADA) 74th Scientific Sessions

This coverage is not sanctioned by, nor a part of, the American Diabetes Association.
Medscape Medical News > Conference News
First-Ever ADA Guidance Specifically for Type 1 Diabetes
Miriam E. Tucker
June 16, 2014

Editors' Recommendations
When Do Patients With Type 1 Diabetes Need Statins?
Practical Steps to Improving the Management of Type 1 Diabetes
Topic Alert
Receive an email from Medscape whenever new articles on this topic are available.
Add Diabetes, Type 1 to My Topic Alert
Drug & Reference Information
Pediatric Type 1 Diabetes Mellitus
Arthritis as a Manifestation of Systemic Disease
Diabetic Lumbosacral Plexopathy
SAN FRANCISCO A new position statement from the American Diabetes
Association (ADA) provides the first-ever guidance specific to the management of
type 1 diabetes in all age groups, including a new HbA
1c
target for children.
"Type 1 Diabetes Through the Life Span: A Position Statement of the American
Diabetes Association" was released June 16 at a press briefing held during the
American Diabetes Association 2014 Scientific Sessions and also simultaneously
published online in Diabetes Care.
A new pediatric glycemic control target of HbA
1c
less than 7.5% across all ages
replaces previous guidelines that had called for different targets by age (less than
8.5% for children aged under 6 years, less than 8% for those aged 6 to 12 years, and
less than 7.5% for adolescents between the ages of 13 and 19 years).
The previous guidance is based on outdated information, Lori M.B. Laffel, MD, chief
of the pediatric, adolescent, and young adult section of the Joslin Diabetes Center and
associate professor of pediatrics at Harvard Medical School, said at the briefing.
"Those targets were based on experience with severe hypoglycemia in a distant era,"
Dr. Laffel said, noting that modern technology such as insulin analogs, insulin pumps,
and continuous glucose monitoring now allow for tighter control with less risk for
hypoglycemia.
Moreover, new evidence suggests that rates of hypoglycemia aren't increased in the
youngest patients, nor in those with lower HbA
1c
levels. And research now shows
increased evidence of acute adverse central nervous system effects of hyperglycemia,
Dr. Laffel said.
The new HbA
1c
target of less than 7.5% across all pediatric age groups is now
harmonized with that of the International Society for Pediatric and Adolescent
Diabetes, the Pediatric Endocrine Society, and the International Diabetes Federation.
The adult HbA
1c
target of less than 7% for type 1 diabetes remains the same, with
individualized lower or higher targets based on patient need.
"We are so pleased to be able to have offered a unified target for the pediatric
population and even more pleased to have a single set of guidelines that will cross the
entire lifespan for our patients with type 1 diabetes so we can be assured as we pass
our patients to our adult providers we will all be singing the same song," Dr. Laffel
said.
Addressing Adults' Need for Diabetes Supplies
The impetus for the new statement came from recognition of the dearth of information
specific to type 1 diabetes in adults and the frequent and often inappropriate
extrapolation of evidence from type 2 diabetes studies to type 1.
"We have this growing population of type 1s who are being treated like type 2s, and
it's not the same disease," coauthor Anne L. Peters, MD, professor of medicine at the
Keck School of Medicine, University of Southern California, Los Angeles, told
Medscape Medical News.
Examples include universal recommendations for statin use and LDL-cholesterol
targets derived from type 2 populations and for which there is little evidence in type 1
patients, and limitations on insurance reimbursement for test strips.
The new statement says that "regardless of age, individuals may require 10 or more
strips daily to monitor for hypoglycemia, assess insulin needs prior to eating, and
determine if their blood glucose levels [are] safe enough for overnight sleeping."
It also gives level A evidence that continuous glucose monitoring "is a useful tool to
reduce HbA
1c
levels in adults without increasing hypoglycemia and can reduce
glycemic excursions in children."
"The point of this was to allow type 1s to get the supplies they need," Dr. Peters told
Medscape Medical News.
There are an estimated 3 million individuals with type 1 diabetes in the US, of whom
only about 160,000 are children. But the exact number of adults including both
those diagnosed in childhood and in adulthood is unknown, because many are seen
in primary-care settings.
"The pediatric type 1s get all the press, but many more are adults," said Dr. Peters,
adding that the diagnosis among those with adult-onset diabetes is often unclear.
M. Sue Kirkman, MD, professor of medicine at the University of North Carolina,
Chapel Hill, agrees.
"I have to say as an adult endocrinologist, it has driven me crazy for a long time that
everyone refers to type 1 diabetes as a pediatric disease....We do need to remember
the vast majority of people with type 1 in this country are adults."
It's estimated that between a third and a half of new-onset type 1 cases are diagnosed
after age 18, and that most who are diagnosed as children are living to adulthood and
old age.
"Once they turn 18 or 21 they don't just disappear," Dr. Kirkman said.
Advice for Primary-Care Physicians on Managing Type 1
Dr. Peters noted that much of the new clinical research in type 1 diabetes is now being
funded by the Leona M. and Harry B. Helmsley Charitable Trust. "Part of this process
is to drive research, and the other part is to take the data we know and make it
clinical. So, the document includes management guidance for primary-care physicians
in particular," she noted.
The statement is meant to serve as a checklist for clinicians. It provides detailed
information about diagnosis and management, screening for long-term complications,
workplace management, diabetes in older adults, and pregnancy.
"At the very least, if [clinicians] evaluate a patient the way we ask, it will be a big
step forward," Dr. Peters told Medscape Medical News.
Jane L. Chiang, MD, senior vice president for medical and community affairs at the
American Diabetes Association, told the media during the press briefing, "We want
all of you to know the ADA is very committed to patients with type 1 diabetes. We
really want to separate out the 2 types of diabetes."
"Reimbursement is different, care is different, and we really want to highlight
that....There really aren't very clear evidence-based recommendations on what patients
with type 1 diabetes need. We think a lot of clinical research needs to be done. This is
just the beginning."
Dr. Kirkman received research support from Novo Nordisk (to the University of North
Carolina) for a study of an investigational drug for type 1 diabetes. In 20132014,
Dr. Laffel received grant support from Bayer Diabetes Care; served as a
consultant/advisory board member for Bristol-Myers Squibb/AstraZeneca, Sanofi,
Novo Nordisk, and Boehringer Ingelheim; and served as a consultant for Johnson &
Johnson, LifeScan/Animas, Lilly, Menarini, and Dexcom. In the past year, Dr. Peters
consulted with Abbott Diabetes Care, BD, Janssen, Lilly, Medscape,
MedtronicMiniMed, NovoNordisk, Sanofi, and Takeda; has been on the speaker's
bureau for Bristol-Myers Squibb/AstraZeneca and Novo Nordisk; and received grant
funding from the MedtronicMiniMed Foundation. No other potential conflicts of
interest relevant to this article were reported.
Diabetes Care. Published online June 16, 2014.